AU5750490A – Production of erythropoietin
– Google Patents
AU5750490A – Production of erythropoietin
– Google Patents
Production of erythropoietin
Info
Publication number
AU5750490A
AU5750490A
AU57504/90A
AU5750490A
AU5750490A
AU 5750490 A
AU5750490 A
AU 5750490A
AU 57504/90 A
AU57504/90 A
AU 57504/90A
AU 5750490 A
AU5750490 A
AU 5750490A
AU 5750490 A
AU5750490 A
AU 5750490A
Authority
AU
Australia
Prior art keywords
erythropoietin
production
Prior art date
1983-12-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU57504/90A
Inventor
Fu-Kuen Lin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen K A Inc
Original Assignee
Kirin Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
1983-12-13
Filing date
1990-06-15
Publication date
1990-10-04
Family has litigation
First worldwide family litigation filed
litigation
Critical
https://patents.darts-ip.com/?family=27504819&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU5750490(A)
«Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
1984-11-30
Priority claimed from US06/675,298
external-priority
patent/US4703008A/en
1990-06-15
Application filed by Kirin Amgen Inc
filed
Critical
Kirin Amgen Inc
1990-10-04
Publication of AU5750490A
publication
Critical
patent/AU5750490A/en
Status
Abandoned
legal-status
Critical
Current
Links
Espacenet
Global Dossier
Discuss
Classifications
C—CHEMISTRY; METALLURGY
C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
C12N15/09—Recombinant DNA-technology
C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P7/00—Drugs for disorders of the blood or the extracellular fluid
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P7/00—Drugs for disorders of the blood or the extracellular fluid
A61P7/06—Antianaemics
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
C07K14/475—Growth factors; Growth regulators
C07K14/505—Erythropoietin [EPO]
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07K—PEPTIDES
C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
C—CHEMISTRY; METALLURGY
C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
C12N15/09—Recombinant DNA-technology
C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
C12N15/70—Vectors or expression systems specially adapted for E. coli
C—CHEMISTRY; METALLURGY
C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
C12N15/09—Recombinant DNA-technology
C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
A—HUMAN NECESSITIES
A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
A61K38/00—Medicinal preparations containing peptides
C—CHEMISTRY; METALLURGY
C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
C12N2800/00—Nucleic acids vectors
C12N2800/10—Plasmid DNA
C12N2800/108—Plasmid DNA episomal vectors
AU57504/90A
1983-12-13
1990-06-15
Production of erythropoietin
Abandoned
AU5750490A
(en)
Applications Claiming Priority (8)
Application Number
Priority Date
Filing Date
Title
US56102483A
1983-12-13
1983-12-13
US561024
1983-12-13
US58218584A
1984-02-21
1984-02-21
US582185
1984-02-21
US65584184A
1984-09-28
1984-09-28
US655841
1984-09-28
US06/675,298
US4703008A
(en)
1983-12-13
1984-11-30
DNA sequences encoding erythropoietin
US675298
1984-11-30
Related Parent Applications (1)
Application Number
Title
Priority Date
Filing Date
AU37467/85A
Division
AU600650C
(en)
1983-12-13
1984-12-11
Polypeptides of erythropoietin
Related Child Applications (2)
Application Number
Title
Priority Date
Filing Date
AU20421/92A
Division
AU657555B2
(en)
1983-12-13
1992-07-20
Production of erythropoietin
AU52722/93A
Division
AU5272293A
(en)
1983-12-13
1993-12-23
Production of erythropoietin
Publications (1)
Publication Number
Publication Date
AU5750490A
true
AU5750490A
(en)
1990-10-04
Family
ID=27504819
Family Applications (5)
Application Number
Title
Priority Date
Filing Date
AU57504/90A
Abandoned
AU5750490A
(en)
1983-12-13
1990-06-15
Production of erythropoietin
AU20421/92A
Expired
AU657555B2
(en)
1983-12-13
1992-07-20
Production of erythropoietin
AU52722/93A
Abandoned
AU5272293A
(en)
1983-12-13
1993-12-23
Production of erythropoietin
AU10074/95A
Abandoned
AU1007495A
(en)
1983-12-13
1995-01-06
Production of erythropoietin
AU36125/97A
Abandoned
AU3612597A
(en)
1983-12-13
1997-08-29
Production of erythropoietin
Family Applications After (4)
Application Number
Title
Priority Date
Filing Date
AU20421/92A
Expired
AU657555B2
(en)
1983-12-13
1992-07-20
Production of erythropoietin
AU52722/93A
Abandoned
AU5272293A
(en)
1983-12-13
1993-12-23
Production of erythropoietin
AU10074/95A
Abandoned
AU1007495A
(en)
1983-12-13
1995-01-06
Production of erythropoietin
AU36125/97A
Abandoned
AU3612597A
(en)
1983-12-13
1997-08-29
Production of erythropoietin
Country Status (15)
Country
Link
US
(3)
US5441868A
(en)
EP
(1)
EP0148605B2
(en)
JP
(9)
JPH0655136B2
(en)
AU
(5)
AU5750490A
(en)
CA
(1)
CA1339047C
(en)
CY
(1)
CY1643A
(en)
DE
(1)
DE3482828D1
(en)
ES
(1)
ES8802329A1
(en)
HK
(1)
HK20093A
(en)
IL
(1)
IL73785A
(en)
MX
(1)
MX9203598A
(en)
NL
(1)
NL930128I1
(en)
NZ
(1)
NZ210501A
(en)
SG
(1)
SG92891G
(en)
WO
(1)
WO1985002610A1
(en)
Cited By (1)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
AU646822B2
(en)
*
1989-10-13
1994-03-10
Kirin-Amgen Inc.
Erythropoietin isoforms
Families Citing this family (353)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
ATE56471T1
(en)
1980-04-03
1990-09-15
Biogen Inc
DNA SEQUENCES, RECOMBINANT DNA MOLECULES AND METHODS OF PRODUCTION OF HUMAN FIBROBLAST INTERFERON.
IT1185503B
(en)
*
1984-01-11
1987-11-12
Univ New York
HUMAN Erythropietine ODNA CLONES
IL77081A
(en)
*
1984-12-04
1999-10-28
Genetics Inst
Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
JPS62501010A
(en)
1984-12-04
1987-04-23
ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド
Production method of erythropoietin
US4677195A
(en)
*
1985-01-11
1987-06-30
Genetics Institute, Inc.
Method for the purification of erythropoietin and erythropoietin compositions
US4732889A
(en)
*
1985-02-06
1988-03-22
Chugai Seiyaku Kabushiki Kaisha
Pharmaceutical composition for the treatment of the anemia of rheumatoid arthritis
US4745099A
(en)
*
1985-02-06
1988-05-17
Chugai Seiyaku Kabushiki Kaisha
Pharmaceutical composition for the treatment of the anemia of malignant tumors
GB2177914B
(en)
*
1985-06-04
1989-10-25
Chugai Pharmaceutical Co Ltd
A pharmaceutical composition containing human erythropoietin and a surface active agent for nasal administration for the treatment of anemia
IL79176A
(en)
*
1985-06-20
1992-06-21
Kirin Amgen Inc
Process for the recovery of erythropoietin from a fluid
US6004548A
(en)
1985-08-23
1999-12-21
Amgen, Inc.
Analogs of pluripotent granulocyte colony-stimulating factor
JPS63500636A
(en)
*
1985-08-23
1988-03-10
麒麟麦酒株式会社
DNA encoding multipotent granulocyte colony stimulating factor
US4810643A
(en)
*
1985-08-23
1989-03-07
Kirin- Amgen Inc.
Production of pluripotent granulocyte colony-stimulating factor
US4935350A
(en)
*
1985-11-18
1990-06-19
Amgen
Materials and methods for controlling plasmid copy number and stability
JPS62171696A
(en)
*
1986-01-23
1987-07-28
Sumitomo Chem Co Ltd
Production of human erythropoietin
DE3789678T2
(en)
*
1986-02-27
1994-08-11
Snow Brand Milk Prod Co Ltd
Production of erythropoietin-producing cells and method for producing erythropoietin using these cells.
DK173067B1
(en)
*
1986-06-27
1999-12-13
Univ Washington
Human erythropoietin gene, method of expression thereof in transfected cell lines, the transfected cell lines
GR871029B
(en)
1986-07-14
1987-11-02
Genetics Inst
Novel osteoinductive factors
US4954437A
(en)
*
1986-09-15
1990-09-04
Integrated Genetics, Inc.
Cell encoding recombinant human erythropoietin
US5013718A
(en)
*
1986-11-21
1991-05-07
Amgen, Inc.
Method for treating iron overload using EPO
WO1988005466A2
(en)
*
1987-01-15
1988-07-28
Codon
Tandem gene eukaryotic expression vectors
US4835260A
(en)
*
1987-03-20
1989-05-30
Genetics Institute, Inc.
Erythropoietin composition
JP2791418B2
(en)
1987-12-02
1998-08-27
株式会社ミドリ十字
Method for producing heterologous protein, recombinant DNA, transformant
DE3923963A1
(en)
*
1989-07-20
1991-01-31
Behringwerke Ag
MUTEINE OF HUMAN ERYTHROPOETIN, THEIR PRODUCTION AND THEIR USE
DE3924746A1
(en)
*
1989-07-26
1991-01-31
Behringwerke Ag
ERTHROPOIETIN (EPO) PEPTIDES AND ANTIBODIES THEREFOR
US6932968B1
(en)
1989-07-26
2005-08-23
Dade Behring Marburg Gmbh
Erythropoietin (EPO) peptides and antibodies directed against these
US7217689B1
(en)
1989-10-13
2007-05-15
Amgen Inc.
Glycosylation analogs of erythropoietin
DE4115722A1
(en)
*
1991-05-14
1992-11-19
Boehringer Mannheim Gmbh
SERUM-FREE MEDIUM FOR CULTIVATING SUGAR CELLS
US6270989B1
(en)
1991-11-05
2001-08-07
Transkaryotic Therapies, Inc.
Protein production and delivery
US5968502A
(en)
*
1991-11-05
1999-10-19
Transkaryotic Therapies, Inc.
Protein production and protein delivery
NZ245015A
(en)
*
1991-11-05
1995-12-21
Transkaryotic Therapies Inc
Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
US5728536A
(en)
*
1993-07-29
1998-03-17
St. Jude Children’s Research Hospital
Jak kinases and regulation of Cytokine signal transduction
FR2686899B1
(en)
*
1992-01-31
1995-09-01
Rhone Poulenc Rorer Sa
NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US6670178B1
(en)
1992-07-10
2003-12-30
Transkaryotic Therapies, Inc.
In Vivo production and delivery of insulinotropin for gene therapy
US6531124B1
(en)
1992-07-10
2003-03-11
Transkaryotic Therapies, Inc.
In vivo production and delivery of insulinotropin for gene therapy
EP0659759B1
(en)
*
1992-09-09
1999-12-08
Nippon Kayaku Kabushiki Kaisha
Novel physiologically active substance nk175203, process for producing the same, and pharmaceutical use thereof
WO1994024160A2
(en)
*
1993-04-21
1994-10-27
Brigham And Women’s Hospital
Erythropoietin muteins with enhanced activity
IL110669A
(en)
*
1993-08-17
2008-11-26
Kirin Amgen Inc
Erythropoietin analogs
US8192955B1
(en)
*
1994-01-03
2012-06-05
Genentech, Inc.
Nucleic acids encoding MPL ligand (thrombopoietin), variants, and fragments thereof
US5888774A
(en)
*
1994-12-19
1999-03-30
Cangene Corporation
Recombinant DNA molecules and expression vectors for erythropoietin
IL118201A
(en)
*
1995-05-11
2004-12-15
Roche Diagnostics Gmbh
Preparation comprising a protein with human erythropoietin activity which is free of serum and non-recombinant mammalian protein and process for the preparation thereof
CA2223833C
(en)
*
1995-06-07
2010-12-21
Nicholas C. Wrighton
Compounds and peptides that bind to the erythropoietin receptor
SI0833934T2
(en)
1995-06-15
2013-04-30
Crucell Holland B.V.
Packaging systems for human recombinant adenovirus to be used in gene therapy
EP0752474A1
(en)
*
1995-07-07
1997-01-08
Boehringer Mannheim Gmbh
Nucleic acid coding for CMP-N-acetyl-neuraminic acid hydroxylase and its use for the production of modified glycoproteins
WO1997003200A1
(en)
*
1995-07-07
1997-01-30
Boehringer Mannheim Gmbh
Nucleic acid coding for cmp-n-acetyl-neuraminic acid hydroxylase and its use for the production of modified glycoproteins
ATE247667T1
(en)
1996-03-14
2003-09-15
Genentech Inc
GDNF RECEPTOR AND ITS USE
GB2318352A
(en)
*
1996-06-25
1998-04-22
Dejan Markovic
Polypeptides mimicking the activity of human erythropoietin
US5952226A
(en)
*
1996-11-05
1999-09-14
Modex Therapeutiques
Hypoxia responsive EPO producing cells
US6573055B2
(en)
*
1997-04-21
2003-06-03
Glycozyme, Inc.
Determination of recombinant glycosylated proteins and peptides in biological fluids
US6475725B1
(en)
1997-06-20
2002-11-05
Baxter Aktiengesellschaft
Recombinant cell clones having increased stability and methods of making and using the same
DE19729769A1
(en)
1997-07-11
1999-01-14
Cardiogene Gentherapeutische S
Transfection system, its manufacture and use in somatic gene therapy
US6017876A
(en)
1997-08-15
2000-01-25
Amgen Inc.
Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity
US6897066B1
(en)
*
1997-09-26
2005-05-24
Athersys, Inc.
Compositions and methods for non-targeted activation of endogenous genes
US7316923B1
(en)
1997-09-26
2008-01-08
Athersys, Inc.
Compositions and methods for non-targeted activation of endogenous genes
IL135604A0
(en)
*
1997-10-16
2001-05-20
Univ Georgia
Vectors comprising a magnum-specific promoter for avian transgenesis
DK1037927T3
(en)
1997-12-08
2004-09-06
Emd Lexigen Res Ct Corp
Heterodimeric fusion proteins useful for targeted immunotherapy and general immune stimulation
BR9908096A
(en)
*
1998-02-19
2000-10-31
Eastern Virginia Med School
Recombinant, active, human skin zone protein (hzp3) 3
US7037663B2
(en)
*
1998-02-19
2006-05-02
Eastern Virginia Medical School
Human zona pellucida protein 3 and uses thereof
SI0937456T1
(en)
1998-02-23
2004-12-31
Cilag Ag International
Erythropoietin liposomal dispersion
US20030105294A1
(en)
*
1998-02-25
2003-06-05
Stephen Gillies
Enhancing the circulating half life of antibody-based fusion proteins
KR100434729B1
(en)
*
1998-03-18
2004-11-03
주식회사 엘지생명과학
Method for improving production yield of erythropoietin from chinese hamster ovary(cho) by adding natural extracts in serum free medium, while reducing production cost
WO1999050432A1
(en)
*
1998-03-27
1999-10-07
Cytos Biotechnology Ag
Inducible alphaviral gene expression system
AR019025A1
(en)
1998-04-09
2001-12-26
Roche Diagnostics Gmbh
USE OF ERYTHROPOYETIN IN LOW DOSE TO PRODUCE A PHARMACEUTICAL PREPARATION FOR THE TREATMENT OF HEMOCROMATOSIS, COMBINED PHARMACEUTICAL PREPARATION USED ACCORDING TO SUCH USE AND PHARMACEUTICAL UNIT PACKAGING CONTAINING THE PHARMACEUTICAL COMBINED PREPARED REFERENCE
ATE329622T1
(en)
*
1998-04-15
2006-07-15
Lexigen Pharm Corp
ENHANCEMENT OF ANTIBODY-CYTOKINE-FUSION PROTEIN-MEDIATED IMMUNE RESPONSE BY CO-ADMINISTRATION WITH AN ANGIOGENESIS HIBITOR
USRE40911E1
(en)
1998-04-22
2009-09-08
Cornell Research Foundation, Inc.
Canine erythropoietin gene and recombinant protein
US6696411B1
(en)
*
1998-04-22
2004-02-24
Cornell Research Foundation, Inc.
Canine erythropoietin gene and recombinant protein
WO1999066054A2
(en)
*
1998-06-15
1999-12-23
Genzyme Transgenics Corp.
Erythropoietin analog-human serum albumin fusion protein
US20050181482A1
(en)
*
2004-02-12
2005-08-18
Meade Harry M.
Method for the production of an erythropoietin analog-human IgG fusion proteins in transgenic mammal milk
US6541033B1
(en)
1998-06-30
2003-04-01
Amgen Inc.
Thermosensitive biodegradable hydrogels for sustained delivery of leptin
JP2002521461A
(en)
*
1998-07-29
2002-07-16
インビトロゲン・コーポレーション
Regulated expression of recombinant proteins using RNA viruses
EP0984062A1
(en)
*
1998-09-04
2000-03-08
Cytos Biotechnology AG
Production of human erythropoietin
US6420339B1
(en)
1998-10-14
2002-07-16
Amgen Inc.
Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6660843B1
(en)
1998-10-23
2003-12-09
Amgen Inc.
Modified peptides as therapeutic agents
US7304150B1
(en)
1998-10-23
2007-12-04
Amgen Inc.
Methods and compositions for the prevention and treatment of anemia
US6777205B1
(en)
1998-11-06
2004-08-17
Sterrenbeld Biotechnologie North America, Inc.
Host cells expressing recombinant human erythropoietin
BR9905867A
(en)
*
1998-11-06
2001-01-23
Bio Sidus S A
Recombinant human erythropoietin-producing cell line and the recombinant human erythropoietin produced by this cell
BR9917606A
(en)
1998-11-06
2002-12-31
Bio Sidus S A
Procedure for the purification of recombinant human erythropoietin from cell culture supernatants and recombinant human erythropoietin obtained with such procedure
BR9905868A
(en)
1998-11-06
2001-01-23
Bio Sidus S A
Mass culture procedure for mammalian cells to obtain recombinant human erythropoietin and recombinant human erythropoietin obtained with such procedure
DE19857609A1
(en)
1998-12-14
2000-06-15
Hannelore Ehrenreich
Use of erythropoietin for the treatment of human cerebral ischemia
US6245740B1
(en)
1998-12-23
2001-06-12
Amgen Inc.
Polyol:oil suspensions for the sustained release of proteins
US6451346B1
(en)
*
1998-12-23
2002-09-17
Amgen Inc
Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
DE19905501B4
(en)
1999-02-10
2005-05-19
MediGene AG, Gesellschaft für molekularbiologische Kardiologie und Onkologie
A method of producing a recombinant adeno-associated virus, suitable compositions therefor, and use for the manufacture of a medicament
US7345019B1
(en)
*
1999-04-13
2008-03-18
The Kenneth S. Warren Institute, Inc.
Modulation of excitable tissue function by peripherally administered erythropoietin
US7410941B1
(en)
1999-04-13
2008-08-12
The Kenneth S. Warren Institute, Inc.
Methods for treatment of neurodegenerative conditions by peripherally administered erythropoietin
US7604960B2
(en)
*
1999-04-15
2009-10-20
Crucell Holland B.V.
Transient protein expression methods
US7297680B2
(en)
*
1999-04-15
2007-11-20
Crucell Holland B.V.
Compositions of erythropoietin isoforms comprising Lewis-X structures and high sialic acid content
US6855544B1
(en)
*
1999-04-15
2005-02-15
Crucell Holland B.V.
Recombinant protein production in a human cell
US20050170463A1
(en)
*
1999-04-15
2005-08-04
Abraham Bout
Recombinant protein production in permanent amniocytic cells that comprise nucleic acid encoding adenovirus E1A and E1B proteins
US8236561B2
(en)
*
1999-04-15
2012-08-07
Crucell Holland B.V.
Efficient production of IgA in recombinant mammalian cells
US20050164386A1
(en)
*
1999-04-15
2005-07-28
Uytdehaag Alphonsus G.
Overexpression of enzymes involved in post-translational protein modifications in human cells
EP1177285A1
(en)
*
1999-05-07
2002-02-06
Genentech, Inc.
Chimpanzee erythropoietin (chepo) polypeptides and nucleic acids encoding the same
US6831060B2
(en)
1999-05-07
2004-12-14
Genentech, Inc.
Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
US6555343B1
(en)
1999-05-07
2003-04-29
Genentech Inc.
Chimpanzee erythropoietin (CHEPO) polypeptides and nucleic acids encoding the same
AT409379B
(en)
1999-06-02
2002-07-25
Baxter Ag
MEDIUM FOR PROTEIN- AND SERUM-FREE CELL CULTURE
US7067110B1
(en)
1999-07-21
2006-06-27
Emd Lexigen Research Center Corp.
Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
SK782002A3
(en)
*
1999-07-21
2003-08-05
Lexigen Pharm Corp
FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US6737519B1
(en)
1999-07-30
2004-05-18
Genome Therapeutics Corporation
Human genes relating to respiratory diseases and obesity
US8106098B2
(en)
*
1999-08-09
2012-01-31
The General Hospital Corporation
Protein conjugates with a water-soluble biocompatible, biodegradable polymer
DE60025832T2
(en)
*
1999-08-09
2006-08-31
Emd Lexigen Research Center Corp., Billerica
MULTIPLE CYTOKINE ANTIBODIES COMPLEX
AU2154401A
(en)
1999-11-12
2001-05-30
Merck Patent Gmbh
Erythropoietin forms with improved properties
US20050202538A1
(en)
*
1999-11-12
2005-09-15
Merck Patent Gmbh
Fc-erythropoietin fusion protein with improved pharmacokinetics
US6703480B1
(en)
1999-11-24
2004-03-09
Palani Balu
Peptide dimers as agonists of the erythropoientin (EPO) receptor, and associated methods of synthesis and use
US7521220B2
(en)
*
1999-11-26
2009-04-21
Crucell Holland B.V.
Production of vaccines
US7192759B1
(en)
*
1999-11-26
2007-03-20
Crucell Holland B.V.
Production of vaccines
US7527961B2
(en)
*
1999-11-26
2009-05-05
Crucell Holland B.V.
Production of vaccines
AU1647501A
(en)
1999-12-10
2001-06-18
Cytos Biotechnology Ag
Replicon based activation of endogenous genes
DE60122286T2
(en)
*
2000-02-11
2007-08-02
Merck Patent Gmbh
INCREASING THE CIRCULATORY HALF-TIME OF ANTIBODY-BASED FUSION PROTEINS
WO2001079480A1
(en)
*
2000-04-12
2001-10-25
Human Genome Sciences, Inc.
Albumin fusion proteins
US20050100991A1
(en)
*
2001-04-12
2005-05-12
Human Genome Sciences, Inc.
Albumin fusion proteins
IES20010462A2
(en)
*
2000-05-12
2001-11-14
Cyril John Higgins
Use of the world wide web
WO2002002143A2
(en)
*
2000-06-29
2002-01-10
Lexigen Pharmaceuticals Corp.
Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agents
CA2415713A1
(en)
*
2000-07-13
2002-01-24
Invitrogen Corporation
Methods and compositions for rapid protein and peptide extraction and isolation using a lysis matrix
US7622503B2
(en)
2000-08-24
2009-11-24
University Of Tennessee Research Foundation
Selective androgen receptor modulators and methods of use thereof
US7919647B2
(en)
2000-08-24
2011-04-05
University Of Tennessee Research Foundation
Selective androgen receptor modulators and methods of use thereof
US7855229B2
(en)
*
2000-08-24
2010-12-21
University Of Tennessee Research Foundation
Treating wasting disorders with selective androgen receptor modulators
US7645898B2
(en)
*
2000-08-24
2010-01-12
University Of Tennessee Research Foundation
Selective androgen receptor modulators and method of use thereof
EP1326969B1
(en)
2000-09-25
2009-04-15
Genetronics, Inc.
Improved system for regulation of transgene expression
US7087224B2
(en)
2000-10-31
2006-08-08
Amgen Inc.
Method of treating anemia by administering IL-1ra
AU2002233230B2
(en)
2000-12-20
2007-02-01
F. Hoffmann-La Roche Ag
Erythropoietin conjugates
US20030072737A1
(en)
*
2000-12-29
2003-04-17
Michael Brines
Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
US7767643B2
(en)
*
2000-12-29
2010-08-03
The Kenneth S. Warren Institute, Inc.
Protection, restoration, and enhancement of erythropoietin-responsive cells, tissues and organs
US6531121B2
(en)
2000-12-29
2003-03-11
The Kenneth S. Warren Institute, Inc.
Protection and enhancement of erythropoietin-responsive cells, tissues and organs
KR100399337B1
(en)
*
2001-02-07
2003-09-26
드림바이오젠 주식회사
Method for Cell-free Protein Post-translational Modification
WO2002072605A2
(en)
2001-03-07
2002-09-19
Merck Patent Gmbh
Expression technology for proteins containing a hybrid isotype antibody moiety
DE10112825A1
(en)
2001-03-16
2002-10-02
Fresenius Kabi De Gmbh
HESylation of active ingredients in aqueous solution
US6992174B2
(en)
*
2001-03-30
2006-01-31
Emd Lexigen Research Center Corp.
Reducing the immunogenicity of fusion proteins
EP1383785B1
(en)
2001-05-03
2011-03-16
Merck Patent GmbH
Recombinant tumor specific antibody and use thereof
US20030143191A1
(en)
*
2001-05-25
2003-07-31
Adam Bell
Chemokine beta-1 fusion proteins
EP1421104A4
(en)
*
2001-08-02
2005-08-24
Trinity Biomedical Technology
Human zona pellucida proteins and methods of their use in diagnosing male infertility
US20030104996A1
(en)
*
2001-08-30
2003-06-05
Tiansheng Li
L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
AU2002325712C1
(en)
*
2001-08-30
2008-07-31
Stem Cell Therapeutics Inc.
Differentiation of neural stem cells and therapeutic use theeof
CA2460184A1
(en)
*
2001-09-14
2003-03-27
Stem Cell Therapeutics Inc.
Prolactin induced increase in neural stem cell numbers and therapeutical use thereof
AR036402A1
(en)
*
2001-09-18
2004-09-08
Stem Cell Therapeutics Inc
EFFECT OF GROWTH HORMONE AND IGF-1 ON NEURONAL MOTHER CELLS.
CA2466881A1
(en)
*
2001-11-28
2003-06-05
Sandoz Gmbh
Cell culture process
BR0214650A
(en)
*
2001-12-04
2005-05-03
Merck Patent Gmbh
Modulated selectivity immunocytokines
US20070161608A1
(en)
*
2001-12-06
2007-07-12
Dalton James T
Selective androgen receptor modulators for treating muscle wasting
US8853266B2
(en)
2001-12-06
2014-10-07
University Of Tennessee Research Foundation
Selective androgen receptor modulators for treating diabetes
NZ533124A
(en)
*
2001-12-07
2005-11-25
Crucell Holland B
Production of viruses, viral isolates and vaccines
WO2005003296A2
(en)
2003-01-22
2005-01-13
Human Genome Sciences, Inc.
Albumin fusion proteins
AU2002364587A1
(en)
*
2001-12-21
2003-07-30
Human Genome Sciences, Inc.
Albumin fusion proteins
AU2002364586A1
(en)
2001-12-21
2003-07-30
Delta Biotechnology Limited
Albumin fusion proteins
KR101032589B1
(en)
2002-01-17
2011-05-06
론자 바이올로직스 피엘씨
Glutamine-auxothrophic human cells capable of producing proteins and capable of growing in a glutamine-free medium
DE10209821A1
(en)
2002-03-06
2003-09-25
Biotechnologie Ges Mittelhesse
Coupling of proteins to a modified polysaccharide
DE10209822A1
(en)
2002-03-06
2003-09-25
Biotechnologie Ges Mittelhesse
Coupling of low molecular weight substances to a modified polysaccharide
US20030191056A1
(en)
2002-04-04
2003-10-09
Kenneth Walker
Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
WO2003094858A2
(en)
*
2002-05-13
2003-11-20
Modigenetech Ltd.
Ctp-extended erythropoietin
NZ537306A
(en)
*
2002-07-01
2008-11-28
Kenneth S Warren Inst Inc
Compositions comprising mutein recombinant tissue protective cytokines having one or more amino acid substitutions facilitating transport of a molecule via transcytosis across an endothelial cell barrier
ES2398706T3
(en)
2002-07-09
2013-03-21
Baxter International Inc.
Animal protein free medium for cell culture
DE10234192B4
(en)
2002-07-26
2009-11-26
Epoplus Gmbh Co.Kg
Use of erythropoietin
AU2003250705A1
(en)
*
2002-07-31
2004-02-16
Stem Cell Therapeutics Inc.
Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
US7344858B2
(en)
*
2002-08-31
2008-03-18
Cj Corp
Glycosylated human granulocyte colony-stimulating factor (G-CSF) isoform
ES2343518T3
(en)
*
2002-09-09
2010-08-03
Hanall Biopharma Co., Ltd.
ALFA INTERFERATED POLYPEPTIDES MODIFIED PROTEASAS RESISTANT.
DE20321793U1
(en)
2002-09-11
2010-06-02
Fresenius Kabi Deutschland Gmbh
Hydroxyalkyl starch derivatives
RU2329274C2
(en)
2002-09-11
2008-07-20
Фрезениус Каби Дойчланд Гмбх
Method of obtaining derivatives of hydroxyalkyl starch
EP1681303B1
(en)
2002-09-11
2013-09-04
Fresenius Kabi Deutschland GmbH
HASylated polypeptides, especially HASylated erythropoietin
US7538092B2
(en)
2002-10-08
2009-05-26
Fresenius Kabi Deutschland Gmbh
Pharmaceutically active oligosaccharide conjugates
KR101086660B1
(en)
*
2002-12-17
2011-11-24
메르크 파텐트 게엠베하
Humanized antibody h14.18 of the mouse 14.18 antibody binding to gd2 and its fusion with il-2
BRPI0406995A
(en)
*
2003-02-03
2006-01-10
Japan Immuno Inc
High expression vector for animal cells
US8084424B2
(en)
*
2003-04-09
2011-12-27
University Of Utah Research Foundation
Compositions and methods related to erythropoietin
US7459152B2
(en)
*
2003-04-23
2008-12-02
Rush University Medical Center
Erythropoietin administration to improve graft survival
EP1623023B1
(en)
*
2003-05-09
2008-11-12
Crucell Holland B.V.
Cultures of e1-immortalized cells and processes for culturing the same to increase product yields therefrom
ES2395413T3
(en)
*
2003-05-12
2013-02-12
Affymax, Inc.
Peptides that bind to the erythropoietin receptor
JP2007530440A
(en)
*
2003-05-12
2007-11-01
アフィーマックス・インコーポレイテッド
Novel poly (ethylene glycol) modified compounds and uses thereof
DE602004020610D1
(en)
2003-05-12
2009-05-28
Affymax Inc
NEW PEPTIDE BINDING TO THE ERYTHROPOIETIN RECEPTOR
BRPI0411166A
(en)
*
2003-05-12
2006-07-18
Affymax Inc
compound comprising a peptide moiety, a spacer moiety and a water soluble polymer moiety and a pharmaceutical composition comprising such a compound
EP1626992B1
(en)
*
2003-05-23
2010-06-02
Crucell Holland B.V.
Production of recombinant igm in per.c6 cells
NZ543859A
(en)
2003-06-10
2008-01-31
Lg Life Sciences Ltd
Aqueous formulation that has storage stability over a long period without serum albumin comprising human erythropoietin; non-ionic surfactant, polyhydric alcohol, neutral amino acid and sugar alcohol as stabilizers
EP1660631B1
(en)
*
2003-08-01
2013-04-24
Life Technologies Corporation
Compositions and methods for purifying short rna molecules
WO2005014655A2
(en)
2003-08-08
2005-02-17
Fresenius Kabi Deutschland Gmbh
Conjugates of hydroxyalkyl starch and a protein
AU2004277954A1
(en)
2003-09-29
2005-04-14
The Kenneth S Warren Institute, Inc.
Tissue protective cytokines for the treatment and prevention of sepsis and the formation of adhesions
WO2005067889A1
(en)
2003-12-30
2005-07-28
Durect Corporation
Polymeric implants, preferably containing a mixture of peg and plg, for controlled release of active agents, preferably a gnrh
EP2233150B1
(en)
2003-12-30
2016-09-07
Augustinus Bader
Erythropoietin for use in the treatment of wounds or the transplantation of cells
AU2004309063B2
(en)
*
2003-12-31
2010-10-28
Merck Patent Gmbh
Fc-erythropoietin fusion protein with improved pharmacokinetics
DE102004004509B4
(en)
2004-01-23
2010-07-01
Epoplus Gmbh Co.Kg
Use of low dose erythropoietin to stimulate endothelial progenitor cells as well as organ regeneration and progression slowing of end organ damage
EP1740202B1
(en)
*
2004-02-13
2012-05-09
Stem Cell Therapeutics Corp.
Use of luteinizing hormone (lh) and chorionic gonadotropin (hcg) for proliferation of neural stem cells and neurogenesis
US7255288B2
(en)
*
2004-03-08
2007-08-14
Wan Shan Chan
Aroma therapy for fountain
CN1946742A
(en)
2004-03-11
2007-04-11
弗雷泽纽斯卡比德国有限公司
Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination
CN102302787A
(en)
2004-03-11
2012-01-04
费森尤斯卡比德国有限公司
Conjugates of hydroxyalkyl starch and a protein
US7588745B2
(en)
*
2004-04-13
2009-09-15
Si Options, Llc
Silicon-containing products
US20110237664A1
(en)
*
2004-06-07
2011-09-29
Dalton James T
Selective androgen receptor modulators for treating diabetes
US9884038B2
(en)
2004-06-07
2018-02-06
University Of Tennessee Research Foundation
Selective androgen receptor modulator and methods of use thereof
US9889110B2
(en)
2004-06-07
2018-02-13
University Of Tennessee Research Foundation
Selective androgen receptor modulator for treating hormone-related conditions
WO2009100255A2
(en)
2008-02-08
2009-08-13
Ambrx, Inc.
Modified leptin polypeptides and their uses
US20060094104A1
(en)
2004-10-29
2006-05-04
Leopold Grillberger
Animal protein-free media for cultivation of cells
WO2006062685A2
(en)
*
2004-11-11
2006-06-15
Affymax, Inc.
Novel peptides that bind to the erythropoietin receptor
WO2006060148A2
(en)
*
2004-11-11
2006-06-08
Affymax, Inc.
Novel peptides that bind to the erythropoietin receptor
WO2006061853A2
(en)
*
2004-12-10
2006-06-15
Serum Institute Of India Limited
Novel erythropoietic compounds and a process for producing erythropoietic compounds
EP1848461A2
(en)
*
2005-02-16
2007-10-31
Nektar Therapeutics Al, Corporation
Conjugates of an epo moiety and a polymer
US8324159B2
(en)
*
2005-06-03
2012-12-04
Affymax, Inc.
Erythropoietin receptor peptide formulations and uses
US7550433B2
(en)
*
2005-06-03
2009-06-23
Affymax, Inc.
Erythropoietin receptor peptide formulations and uses
US7919461B2
(en)
2005-06-03
2011-04-05
Affymax, Inc.
Erythropoietin receptor peptide formulations and uses
BRPI0617117A2
(en)
2005-08-31
2011-07-12
Univ Tennessee Res Foundation
treatment of kidney disease, burns, injuries and spinal cord damage with selective androgen receptor modulators
EP1762250A1
(en)
2005-09-12
2007-03-14
Fresenius Kabi Deutschland GmbH
Conjugates of hydroxyalkyl starch and an active substance, prepared by chemical ligation via thiazolidine
EP1928488A4
(en)
2005-09-27
2009-07-22
Stem Cell Therapeutics Corp
Oligodendrocyte precursor cell proliferation regulated by prolactin
WO2008048671A1
(en)
*
2006-10-18
2008-04-24
University Of Illinois
Embryonic-like stem cells derived from adult human peripheral blood and methods of use
US9388382B2
(en)
*
2005-10-05
2016-07-12
The Board Of Trustees Of The University Of Illinois
Isolation of CD14 negative, CD45 positive and CD117 positive embryonic-like stem cells free of monocytes from human umbilical cord blood mononuclear cells
WO2007060213A2
(en)
*
2005-11-24
2007-05-31
Laboratoires Serono S.A.
Erythropoietin polypeptides and uses thereof
EP2495308A1
(en)
*
2005-12-08
2012-09-05
Amgen Inc.
Improved production of glycoproteins using manganese
ES2629304T3
(en)
*
2006-01-04
2017-08-08
Baxalta Incorporated
Cell culture medium without oligopeptides
US7625564B2
(en)
*
2006-01-27
2009-12-01
Novagen Holding Corporation
Recombinant human EPO-Fc fusion proteins with prolonged half-life and enhanced erythropoietic activity in vivo
DE102006004008A1
(en)
2006-01-27
2007-08-02
Hannelore Prof. Dr. Dr. Ehrenreich
Treating or preventing multiple sclerosis comprises administering erythropoietin for periods separated by intervals in which no erythropoietin is administered
JP2009530234A
(en)
*
2006-03-17
2009-08-27
ステム セル セラピューティクス コーポレイション
Administration regimen for LH or HCG and EPO for the treatment of neurodegenerative diseases
US8546329B2
(en)
2006-03-22
2013-10-01
Chugai Seiyaku Kabushiki Kaisha
Erythropoietin solution preparation
CN101062407A
(en)
2006-04-29
2007-10-31
中国科学院上海生命科学研究院
Function of erythropoietin in the preventing and treating of retinal injury
EP3147278B1
(en)
2006-07-12
2020-02-12
University of Tennessee Research Foundation
Compound for treating breast cancer and progestin-dependent conditions
CN105820231A
(en)
2006-08-04
2016-08-03
普罗龙药品有限责任公司
Modified erythropoietin
CA2661054A1
(en)
2006-08-22
2008-02-28
Chugai Seiyaku Kabushiki Kaisha
Prophylactic and/or therapeutic agents for peripheral neuropathy
BRPI0714526A2
(en)
2006-08-24
2013-04-30
Univ Tennessee Res Foundation
substituted acylanilides and their methods of use
US8454948B2
(en)
2006-09-14
2013-06-04
Medgenics Medical Israel Ltd.
Long lasting drug formulations
AU2007294858B2
(en)
*
2006-09-14
2011-05-12
Medgenics Medical Israel, Ltd
Long lasting drug formulations
WO2008065372A2
(en)
2006-11-28
2008-06-05
Nautilus Biotech, S.A.
Modified erythropoietin polypeptides and uses thereof for treatment
EP2089424B1
(en)
*
2006-12-06
2015-07-01
JCR PHARMACEUTICALS Co., LTD.
Method for production of human erythropoietin
WO2008074851A2
(en)
*
2006-12-19
2008-06-26
Nokad
Method for inhibiting the expression of endogenous erythropoietin (epo)
JP2010517529A
(en)
*
2007-02-02
2010-05-27
アムジエン・インコーポレーテツド
Hepcidin and hepcidin antibody
AR065613A1
(en)
2007-03-09
2009-06-17
Chugai Pharmaceutical Co Ltd
PROTECTION AGENTS FOR TRANSPLANTED ORGANS
US20080260820A1
(en)
*
2007-04-19
2008-10-23
Gilles Borrelly
Oral dosage formulations of protease-resistant polypeptides
EP2167115A2
(en)
2007-06-15
2010-03-31
University Of Zurich
Treatment for alzheimer’s disease
WO2009010107A1
(en)
2007-07-19
2009-01-22
Hannelore Ehrenreich
Use of epo receptor activation or stimulation for the improvement of the edss score in patients with multiple sclerosis
CA2720628A1
(en)
*
2007-07-26
2009-01-29
Novagen Holding Corporation
Fusion proteins having mutated immunoglobulin hinge region
US7968603B2
(en)
2007-09-11
2011-06-28
University Of Tennessee Research Foundation
Solid forms of selective androgen receptor modulators
WO2009043049A2
(en)
*
2007-09-27
2009-04-02
Amgen Inc.
Pharmaceutical formulations
EP3381445B1
(en)
2007-11-15
2023-10-25
Amgen Inc.
Aqueous formulation of antibody stablised by antioxidants for parenteral administration
EP2070950A1
(en)
2007-12-14
2009-06-17
Fresenius Kabi Deutschland GmbH
Hydroxyalkyl starch derivatives and process for their preparation
JP5701064B2
(en)
2008-01-25
2015-04-15
アムジエン・インコーポレーテツド
Ferroportin antibody and method of use thereof
EP2095829A1
(en)
2008-02-27
2009-09-02
LEK Pharmaceuticals D.D.
Selenium containing modifying agents and conjugates
US8653249B2
(en)
2008-02-27
2014-02-18
Fuso Pharmaceutical Industries, Ltd.
Expression vector for mass production of foreign gene-derived protein using animal cell and use thereof
EP2620448A1
(en)
2008-05-01
2013-07-31
Amgen Inc.
Anti-hepcidin antibodies and methods of use
DE102008002210A1
(en)
*
2008-06-04
2009-12-10
Evonik Degussa Gmbh
Process for the fermentative production of erythropoietin
DE102008002209A1
(en)
2008-06-04
2009-12-10
Evonik Degussa Gmbh
Process for the purification of erythropoietin
US8003689B2
(en)
*
2008-06-20
2011-08-23
Gtx, Inc.
Metabolites of selective androgen receptor modulators and methods of use thereof
WO2010034442A1
(en)
2008-09-23
2010-04-01
F. Hoffmann-La Roche Ag
Purification of erythropoietin
US8278418B2
(en)
2008-09-26
2012-10-02
Ambrx, Inc.
Modified animal erythropoietin polypeptides and their uses
US8318167B2
(en)
2008-11-13
2012-11-27
The General Hospital Corporation
Methods and compositions for regulating iron homeostasis by modulation of BMP-6
DE102008054716A1
(en)
2008-12-16
2010-06-17
Evonik Degussa Gmbh
In-process control in a process for the production of EPO
DK2385115T3
(en)
2008-12-22
2015-11-30
Univ Hokkaido Nat Univ Corp
An expression vector for the production of a protein derived from a foreign gene in large quantities using animal cells as well as its use
US20100272816A1
(en)
2009-04-27
2010-10-28
Wolfgang Rudinger
Microcapsules comprising liver cells and erythropoietin, methods for preparing said microcapsules and methods for treating a patient comprising applying said microcapsules to the patient
MX356669B
(en)
2009-05-02
2018-06-08
Genzyme Corp
Gene therapy for neurodegenerative disorders.
US20120264688A1
(en)
2009-09-23
2012-10-18
Walter Hinderer
Process for the purification of recombinant human erythropoietin (epo), epo thus purified and pharmaceutical compositions comprising same
EP2490957B1
(en)
2009-10-23
2016-11-23
Amgen, Inc
Vial adapter and system
KR102513760B1
(en)
2010-06-07
2023-03-27
암젠 인크
Drug delivery device
CN103260649A
(en)
2010-06-15
2013-08-21
迈德詹尼克斯医疗以色列有限公司
Long lasting drug formulations
EA024507B1
(en)
2010-09-28
2016-09-30
Амилин Фармасьютикалс, Ллк
Highly soluble leptins
US9480624B2
(en)
2011-03-31
2016-11-01
Amgen Inc.
Vial adapter and system
PT2699293T
(en)
2011-04-20
2019-05-21
Amgen Inc
Autoinjector apparatus
EP3045188B1
(en)
2011-10-14
2020-12-23
Amgen Inc.
Injector and method of assembly
KR101443257B1
(en)
*
2011-10-18
2014-09-19
주식회사 종근당
Methods for Purifying Erythropoietin Analogs Having Lower Isoelectric Point
US10350139B2
(en)
2011-10-25
2019-07-16
Corning Incorporated
Pharmaceutical glass packaging assuring pharmaceutical sterility
WO2013063287A1
(en)
2011-10-25
2013-05-02
Corning Incorporated
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9969683B2
(en)
2012-07-13
2018-05-15
Gtx, Inc.
Method of treating estrogen receptor (ER)-positive breast cancers with selective androgen receptor modulator (SARMS)
US9622992B2
(en)
2012-07-13
2017-04-18
Gtx, Inc.
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US9744149B2
(en)
2012-07-13
2017-08-29
Gtx, Inc.
Method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMs)
US10258596B2
(en)
2012-07-13
2019-04-16
Gtx, Inc.
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10314807B2
(en)
2012-07-13
2019-06-11
Gtx, Inc.
Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
US10987334B2
(en)
2012-07-13
2021-04-27
University Of Tennessee Research Foundation
Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
ES2818915T3
(en)
2012-07-13
2021-04-14
Oncternal Therapeutics Inc
Method of treating breast cancers with a selective androgen receptor modulator (SARM)
US9650411B2
(en)
2012-08-07
2017-05-16
Kyowa Hakko Kirin Co., Ltd.
Method of purifying protein
CN104822826B
(en)
2012-10-15
2019-04-30
百时美施贵宝公司
The mammalian cell culture process generated for albumen
CA3206182A1
(en)
2012-11-21
2014-05-30
Amgen Inc.
Drug delivery device including insertion member and reservoir
EP2970351B1
(en)
*
2013-03-14
2017-09-13
Translate Bio, Inc.
Ribonucleic acids with 4′-thio-modified nucleotides and related methods
CN105263514B
(en)
2013-03-15
2019-04-26
本质生命科学有限公司
Anti- hepcidin antibody and application thereof
EP2970420A4
(en)
2013-03-15
2016-08-17
Apotex Inc
Enhanced liquid formulation stability of erythropoietin alpha through purification processing
CA2904725C
(en)
2013-03-15
2022-04-12
Amgen Inc.
Drug cassette, autoinjector, and autoinjector system
TWI639453B
(en)
2013-03-15
2018-11-01
美商安美基公司
Cassette for an injector
EP3831427A1
(en)
2013-03-22
2021-06-09
Amgen Inc.
Injector and method of assembly
US9717649B2
(en)
2013-04-24
2017-08-01
Corning Incorporated
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707153B2
(en)
2013-04-24
2017-07-18
Corning Incorporated
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700485B2
(en)
2013-04-24
2017-07-11
Corning Incorporated
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603775B2
(en)
2013-04-24
2017-03-28
Corning Incorporated
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9849066B2
(en)
2013-04-24
2017-12-26
Corning Incorporated
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9713572B2
(en)
2013-04-24
2017-07-25
Corning Incorporated
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707154B2
(en)
2013-04-24
2017-07-18
Corning Incorporated
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9717648B2
(en)
2013-04-24
2017-08-01
Corning Incorporated
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9700486B2
(en)
2013-04-24
2017-07-11
Corning Incorporated
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9707155B2
(en)
2013-04-24
2017-07-18
Corning Incorporated
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9839579B2
(en)
2013-04-24
2017-12-12
Corning Incorporated
Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
EP3036254A1
(en)
2013-08-20
2016-06-29
LEK Pharmaceuticals d.d.
Cell culture medium and process for controlling -amidation and/or c-terminal amino acid cleavage of polypeptides
US10758683B2
(en)
2013-10-24
2020-09-01
Amgen Inc.
Drug delivery system with temperature-sensitive control
EP3060144A1
(en)
2013-10-24
2016-08-31
Medgenics Medical Israel, Ltd
Micro-organs providing sustained delivery of a therapeutic polypeptide and methods of use thereof
ES2744837T3
(en)
2013-10-24
2020-02-26
Amgen Inc
Injector and assembly procedure
US10994112B2
(en)
2014-02-05
2021-05-04
Amgen Inc.
Drug delivery system with electromagnetic field generator
SG10201811702TA
(en)
2014-05-07
2019-01-30
Amgen Inc
Autoinjector with shock reducing elements
SG11201609050UA
(en)
2014-05-30
2016-12-29
Pfizer
Carbonitrile derivatives as selective androgen receptor modulators
SG10201806528QA
(en)
2014-06-03
2018-08-30
Amgen Inc
Controllable drug delivery system and method of use
AU2015321462B2
(en)
2014-09-22
2020-04-30
Intrinsic Lifesciences Llc
Humanized anti-hepcidin antibodies and uses thereof
MX2017004836A
(en)
2014-10-14
2017-07-20
Amgen Inc
Drug injection device with visual and audio indicators.
JP2017538512A
(en)
2014-12-19
2017-12-28
アムジエン・インコーポレーテツド
Drug delivery device including live button or user interface field
EP3848072A1
(en)
2014-12-19
2021-07-14
Amgen Inc.
Drug delivery device with proximity sensor
JP6484345B2
(en)
2015-02-17
2019-03-20
アムジエン・インコーポレーテツド
Drug delivery device with fixation and / or return assisted by vacuum
ES2905870T3
(en)
2015-02-27
2022-04-12
Amgen Inc
Drug delivery device having a needle guard mechanism with an adjustable threshold resistance to movement of the needle guard
WO2017039786A1
(en)
2015-09-02
2017-03-09
Amgen Inc.
Syringe assembly adapter for a syringe
WO2017068051A1
(en)
2015-10-21
2017-04-27
Lek Pharmaceuticals D.D.
Peg-based dendron and process for producing the same
ES2755717T3
(en)
2015-12-09
2020-04-23
Amgen Inc
Autoinjector with signaling cap
US11154661B2
(en)
2016-01-06
2021-10-26
Amgen Inc.
Auto-injector with signaling electronics
EP3429663B1
(en)
2016-03-15
2020-07-15
Amgen Inc.
Reducing probability of glass breakage in drug delivery devices
US11541168B2
(en)
2016-04-29
2023-01-03
Amgen Inc.
Drug delivery device with messaging label
US11389588B2
(en)
2016-05-02
2022-07-19
Amgen Inc.
Syringe adapter and guide for filling an on-body injector
WO2017197222A1
(en)
2016-05-13
2017-11-16
Amgen Inc.
Vial sleeve assembly
US11238150B2
(en)
2016-05-16
2022-02-01
Amgen Inc.
Data encryption in medical devices with limited computational capability
EP3465124A1
(en)
2016-06-03
2019-04-10
Amgen Inc.
Impact testing apparatuses and methods for drug delivery devices
WO2018004842A1
(en)
2016-07-01
2018-01-04
Amgen Inc.
Drug delivery device having minimized risk of component fracture upon impact events
WO2018034784A1
(en)
2016-08-17
2018-02-22
Amgen Inc.
Drug delivery device with placement detection
US20200261643A1
(en)
2016-10-25
2020-08-20
Amgen Inc.
On-body injector
WO2018136398A1
(en)
2017-01-17
2018-07-26
Amgen Inc.
Injection devices and related methods of use and assembly
EP3582825A1
(en)
2017-02-17
2019-12-25
Amgen Inc.
Drug delivery device with sterile fluid flowpath and related method of assembly
US11369736B2
(en)
2017-02-17
2022-06-28
Amgen Inc.
Cannula insertion and retraction mechanisms
WO2018165143A1
(en)
2017-03-06
2018-09-13
Amgen Inc.
Drug delivery device with activation prevention feature
US11571511B2
(en)
2017-03-07
2023-02-07
Amgen Inc.
Insertion mechanism and method of inserting a needle of a drug delivery device
US20200023122A1
(en)
2017-03-09
2020-01-23
Amgen Inc.
Insertion mechanism for drug delivery device
EP3570871B1
(en)
2017-03-20
2020-11-18
H. Hoffnabb-La Roche Ag
Method for in vitro glycoengineering of an erythropoiesis stimulating protein
MX2019011416A
(en)
2017-03-28
2019-11-01
Amgen Inc
Plunger rod and syringe assembly system and method.
WO2018226565A1
(en)
2017-06-08
2018-12-13
Amgen Inc.
Torque driven drug delivery device
US11590294B2
(en)
2017-06-08
2023-02-28
Amgen Inc.
Syringe assembly for a drug delivery device and method of assembly
KR102268647B1
(en)
2017-06-12
2021-06-23
한국코러스 주식회사
A Composition comprising erythropoietin and a method of producing the same
AU2018288604A1
(en)
2017-06-22
2019-11-21
Amgen Inc.
Device activation impact/shock reduction
JP2020525059A
(en)
2017-06-23
2020-08-27
アムジエン・インコーポレーテツド
Electronic drug delivery device including a cap activated by a switch assembly
JP2020527373A
(en)
2017-07-14
2020-09-10
アムジエン・インコーポレーテツド
Needle insertion retreat system with double torsion spring system
EP3655063A1
(en)
2017-07-21
2020-05-27
Amgen Inc.
Gas permeable sealing member for drug container and methods of assembly
EP3658206A1
(en)
2017-07-25
2020-06-03
Amgen Inc.
Drug delivery device with container access system and related method of assembly
MA49677A
(en)
2017-07-25
2021-04-21
Amgen Inc
DRUG DELIVERY DEVICE WITH GEAR MODULE AND ASSOCIATED ASSEMBLY PROCESS
MA49838A
(en)
2017-08-09
2020-06-17
Amgen Inc
DRUG DELIVERY SYSTEM WITH CHAMBER HYDRAULIC-PNEUMATIC PRESSURE
MA49897A
(en)
2017-08-18
2020-06-24
Amgen Inc
ON-BODY INJECTOR WITH STERILE ADHESIVE PATCH
US11103636B2
(en)
2017-08-22
2021-08-31
Amgen Inc.
Needle insertion mechanism for drug delivery device
WO2019070472A1
(en)
2017-10-04
2019-04-11
Amgen Inc.
Flow adapter for drug delivery device
CN111132711B
(en)
2017-10-06
2022-07-01
安进公司
Drug delivery device with interlocking components and related assembly methods
WO2019074579A1
(en)
2017-10-09
2019-04-18
Amgen Inc.
Drug delivery device with drive assembly and related method of assembly
MA50528A
(en)
2017-11-03
2020-09-09
Amgen Inc
SYSTEMS AND APPROACHES TO STERILIZE A DRUG DELIVERY DEVICE
EP3707075A1
(en)
2017-11-06
2020-09-16
Amgen Inc.
Fill-finish assemblies and related methods
US20200261648A1
(en)
2017-11-06
2020-08-20
Amgen Inc.
Drug delivery device with placement and flow sensing
US11191904B2
(en)
2017-11-10
2021-12-07
Amgen Inc.
Plungers for drug delivery devices
CA3084486A1
(en)
2017-11-16
2019-05-23
Amgen Inc.
Autoinjector with stall and end point detection
CA3079540A1
(en)
2017-11-16
2019-05-23
Amgen Inc.
Door latch mechanism for drug delivery device
EP3805396A4
(en)
2018-05-24
2022-03-23
National University Corporation Hokkaido University
Novel vector and use thereof
US10835685B2
(en)
2018-05-30
2020-11-17
Amgen Inc.
Thermal spring release mechanism for a drug delivery device
US11083840B2
(en)
2018-06-01
2021-08-10
Amgen Inc.
Modular fluid path assemblies for drug delivery devices
WO2020023336A1
(en)
2018-07-24
2020-01-30
Amgen Inc.
Hybrid drug delivery devices with grip portion
CN112351804A
(en)
2018-07-24
2021-02-09
安进公司
Delivery device for administering a drug
CN112469454A
(en)
2018-07-24
2021-03-09
安进公司
Delivery device for administering a drug
US20210260279A1
(en)
2018-07-24
2021-08-26
Amgen Inc.
Hybrid drug delivery devices with optional grip portion and related method of preparation
MA53320A
(en)
2018-07-31
2021-11-03
Amgen Inc
FLUID PATH ASSEMBLY FOR DRUG DELIVERY DEVICE
US20210346601A1
(en)
2018-09-24
2021-11-11
Amgen Inc.
Interventional dosing systems and methods
WO2020068476A1
(en)
2018-09-28
2020-04-02
Amgen Inc.
Muscle wire escapement activation assembly for a drug delivery device
JP2022503983A
(en)
2018-10-02
2022-01-12
アムジエン・インコーポレーテツド
Injection system for drug delivery with internal force transmission
CA3112214A1
(en)
2018-10-05
2020-04-09
Amgen Inc.
Drug delivery device having dose indicator
BR112021007016A2
(en)
2018-10-15
2021-07-13
Amgen Inc.
drug delivery device having damping mechanism
US20210346596A1
(en)
2018-10-15
2021-11-11
Amgen Inc.
Platform assembly process for drug delivery device
WO2020091956A1
(en)
2018-11-01
2020-05-07
Amgen Inc.
Drug delivery devices with partial drug delivery member retraction
TW202100191A
(en)
2018-11-01
2021-01-01
美商安進公司
Drug delivery devices with partial needle retraction
CA3113076A1
(en)
2018-11-01
2020-05-07
Amgen Inc.
Drug delivery devices with partial drug delivery member retraction
JP2022529319A
(en)
2019-04-24
2022-06-21
アムジエン・インコーポレーテツド
Syringe sterility confirmation assembly and method
US20220273887A1
(en)
2019-08-23
2022-09-01
Amgen Inc.
Drug delivery device with configurable needle shield engagement components and related methods
WO2022159414A1
(en)
2021-01-22
2022-07-28
University Of Rochester
Erythropoietin for gastroinfestinal dysfunction
CA3217207A1
(en)
2021-05-21
2022-11-24
Amgen Inc.
Method of optimizing a filling recipe for a drug container
WO2023275715A1
(en)
2021-06-30
2023-01-05
Pfizer Inc.
Metabolites of selective androgen receptor modulators
WO2023209074A1
(en)
2022-04-28
2023-11-02
Institut National de la Santé et de la Recherche Médicale
Methods of restoring erythropoiesis in patients suffering from a sf3b1 mutant myelodysplastic syndrome by correcting coasy mis-splicing
Family Cites Families (46)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
US3033753A
(en)
*
1959-08-31
1962-05-08
Wilfrid F White
Erythropoietic factor purification
US3865801A
(en)
*
1973-06-15
1975-02-11
Atomic Energy Commission
Stabilization of urinary erythropoietin using sodium p-aminosalicylate and extracting into phenol
US4237224A
(en)
*
1974-11-04
1980-12-02
Board Of Trustees Of The Leland Stanford Jr. University
Process for producing biologically functional molecular chimeras
US4468464A
(en)
*
1974-11-04
1984-08-28
The Board Of Trustees Of The Leland Stanford Junior University
Biologically functional molecular chimeras
US4264731A
(en)
*
1977-05-27
1981-04-28
The Regents Of The University Of California
DNA Joining method
JPS5455790A
(en)
*
1977-10-05
1979-05-04
Tomoyuki Tajima
Production of erythropoetin
US4254095A
(en)
*
1978-04-27
1981-03-03
Research Corporation
Radioimmunoassay for erythropoietin
US4411994A
(en)
*
1978-06-08
1983-10-25
The President And Fellows Of Harvard College
Protein synthesis
US4273875A
(en)
*
1979-03-05
1981-06-16
The Upjohn Company
Plasmid and process of isolating same
US4293652A
(en)
*
1979-05-25
1981-10-06
Cetus Corporation
Method for synthesizing DNA sequentially
JPS5653696A
(en)
*
1979-10-09
1981-05-13
Ajinomoto Co Inc
Isolation of erythropoietin by adsorption
US4399216A
(en)
*
1980-02-25
1983-08-16
The Trustees Of Columbia University
Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4338397A
(en)
*
1980-04-11
1982-07-06
President And Fellows Of Harvard College
Mature protein synthesis
JPS6045849B2
(en)
*
1980-08-25
1985-10-12
林原 健
Method for producing human erythropoietin
US4568448A
(en)
*
1980-11-26
1986-02-04
Mobil Oil Corporation
Hydrodesulfurization process employing poison-resistant catalyst
US4358535A
(en)
*
1980-12-08
1982-11-09
Board Of Regents Of The University Of Washington
Specific DNA probes in diagnostic microbiology
US4503151A
(en)
*
1980-12-10
1985-03-05
Research Corporation
Recombinant cDNA construction method and hybrid nucleotides useful in cloning
US4394443A
(en)
*
1980-12-18
1983-07-19
Yale University
Method for cloning genes
JPS57149228A
(en)
*
1981-03-11
1982-09-14
Ajinomoto Co Inc
Novel erythropoietin and its preparation
CA1190838A
(en)
*
1981-07-17
1985-07-23
Cavit Akin
Homogeneous nucleic acid hybridization diagnostics by non-radiative energy transfer
CA1180647A
(en)
*
1981-07-17
1985-01-08
Cavit Akin
Light-emitting polynucleotide hybridization diagnostic method
US4442205A
(en)
*
1981-09-22
1984-04-10
The United States Of America As Represented By The Department Of Health And Human Services
Simian virus recombinant that directs the synthesis of hepatitis B surface antigen
AU561343B2
(en)
*
1981-10-19
1987-05-07
Genentech Inc.
Human immune interferon by recombinant dna
GR79202B
(en)
*
1982-05-05
1984-10-22
Genentech Inc
US6936694B1
(en)
*
1982-05-06
2005-08-30
Intermune, Inc.
Manufacture and expression of large structural genes
US4558005A
(en)
*
1982-09-13
1985-12-10
University Patents, Inc.
Monoclonal anti-erythropoietin
AU572108B2
(en)
*
1983-01-19
1988-05-05
Genentech Inc.
Human tpa production using vectors coding for dhfr protein
AU2353384A
(en)
*
1983-01-19
1984-07-26
Genentech Inc.
Amplification in eukaryotic host cells
US4713339A
(en)
*
1983-01-19
1987-12-15
Genentech, Inc.
Polycistronic expression vector construction
US4558006A
(en)
*
1983-02-04
1985-12-10
Kirin-Amgen, Inc.
A.T.C.C. HB8209 and its monoclonal antibody to erythropoietin
JPH0686480B2
(en)
*
1983-02-21
1994-11-02
雪印乳業株式会社
Monoclonal antibody for erythropoietin production
WO1984004330A1
(en)
*
1983-04-22
1984-11-08
Amgen
Secretion of exogenous polypeptides from yeast
US4710473A
(en)
*
1983-08-10
1987-12-01
Amgen, Inc.
DNA plasmids
JPS6043395A
(en)
*
1983-08-19
1985-03-07
Sumitomo Chem Co Ltd
Preparation of erythropoietin
US4695542A
(en)
*
1983-10-04
1987-09-22
Dnax Research Institute Of Molecular And Cellular Biology, Inc.
cDNA clones coding for polypeptides exhibiting multi-lineage cellular growth factor activity
US4757006A
(en)
*
1983-10-28
1988-07-12
Genetics Institute, Inc.
Human factor VIII:C gene and recombinant methods for production
JPH07106156B2
(en)
*
1983-10-28
1995-11-15
ジェネティックス、インスティチュ−ト
Manufacture of factor-VIII and related products
US4703008A
(en)
*
1983-12-13
1987-10-27
Kiren-Amgen, Inc.
DNA sequences encoding erythropoietin
IT1185503B
(en)
*
1984-01-11
1987-11-12
Univ New York
HUMAN Erythropietine ODNA CLONES
US4568488A
(en)
*
1984-01-11
1986-02-04
Lee Huang Sylvia
Reverse immunoaffinity chromatography purification method
GB8407498D0
(en)
*
1984-03-22
1984-05-02
Biogen Nv
High copy number expression vectors
JPS60215632A
(en)
*
1984-04-12
1985-10-29
Japan Found Cancer
Preparation of erythropoietin
IL77081A
(en)
*
1984-12-04
1999-10-28
Genetics Inst
Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin
US4677195A
(en)
*
1985-01-11
1987-06-30
Genetics Institute, Inc.
Method for the purification of erythropoietin and erythropoietin compositions
US4667016A
(en)
*
1985-06-20
1987-05-19
Kirin-Amgen, Inc.
Erythropoietin purification
JP3344027B2
(en)
*
1993-09-21
2002-11-11
ソニー株式会社
Dry etching method
1984
1984-12-10
NZ
NZ210501A
patent/NZ210501A/en
unknown
1984-12-11
WO
PCT/US1984/002021
patent/WO1985002610A1/en
unknown
1984-12-11
IL
IL73785A
patent/IL73785A/en
unknown
1984-12-12
ES
ES538519A
patent/ES8802329A1/en
not_active
Expired
1984-12-12
DE
DE8484308654T
patent/DE3482828D1/en
not_active
Expired – Lifetime
1984-12-12
EP
EP84308654A
patent/EP0148605B2/en
not_active
Expired – Lifetime
1984-12-12
CA
CA000616898A
patent/CA1339047C/en
not_active
Expired – Lifetime
1987
1987-10-23
US
US07/113,179
patent/US5441868A/en
not_active
Expired – Lifetime
1987-12-04
JP
JP62307341A
patent/JPH0655136B2/en
not_active
Expired – Lifetime
1990
1990-06-15
AU
AU57504/90A
patent/AU5750490A/en
not_active
Abandoned
1990-11-21
JP
JP2317592A
patent/JPH03198792A/en
active
Granted
1990-11-21
JP
JP2317593A
patent/JP2655750B2/en
not_active
Expired – Lifetime
1991
1991-11-04
SG
SG928/91A
patent/SG92891G/en
unknown
1992
1992-06-26
MX
MX9203598A
patent/MX9203598A/en
active
IP Right Grant
1992-07-20
AU
AU20421/92A
patent/AU657555B2/en
not_active
Expired
1993
1993-03-11
HK
HK200/93A
patent/HK20093A/en
not_active
IP Right Cessation
1993-05-14
CY
CY1643A
patent/CY1643A/en
unknown
1993-06-21
JP
JP5149531A
patent/JPH0776239B2/en
not_active
Expired – Lifetime
1993-07-01
NL
NL930128C
patent/NL930128I1/en
unknown
1993-12-23
AU
AU52722/93A
patent/AU5272293A/en
not_active
Abandoned
1995
1995-01-06
AU
AU10074/95A
patent/AU1007495A/en
not_active
Abandoned
1995-06-06
US
US08/468,369
patent/US5756349A/en
not_active
Expired – Lifetime
1995-06-06
US
US08/468,381
patent/US5618698A/en
not_active
Expired – Lifetime
1996
1996-03-29
JP
JP8076540A
patent/JP2708099B2/en
not_active
Expired – Lifetime
1997
1997-07-03
JP
JP9178411A
patent/JP2957974B2/en
not_active
Expired – Lifetime
1997-08-04
JP
JP9209391A
patent/JP3017962B2/en
not_active
Expired – Lifetime
1997-08-29
AU
AU36125/97A
patent/AU3612597A/en
not_active
Abandoned
1998
1998-12-16
JP
JP35799598A
patent/JP3276933B2/en
not_active
Expired – Lifetime
2001
2001-06-07
JP
JP2001173139A
patent/JP3375614B2/en
not_active
Expired – Lifetime
Cited By (1)
* Cited by examiner, † Cited by third party
Publication number
Priority date
Publication date
Assignee
Title
AU646822B2
(en)
*
1989-10-13
1994-03-10
Kirin-Amgen Inc.
Erythropoietin isoforms
Also Published As
Publication number
Publication date
MX9203598A
(en)
1992-09-01
JPH0655136B2
(en)
1994-07-27
CY1643A
(en)
1993-05-14
AU5272293A
(en)
1994-03-24
ES538519A0
(en)
1988-05-01
DE3482828D1
(en)
1990-08-30
US5756349A
(en)
1998-05-26
AU600650B2
(en)
1990-08-23
JPH03198792A
(en)
1991-08-29
JPH1095799A
(en)
1998-04-14
JP2957974B2
(en)
1999-10-06
IL73785A
(en)
1992-11-15
JP2655750B2
(en)
1997-09-24
JPS6455190A
(en)
1989-03-02
EP0148605A2
(en)
1985-07-17
EP0148605B2
(en)
1998-12-23
EP0148605B1
(en)
1990-07-25
JP2002045191A
(en)
2002-02-12
AU1007495A
(en)
1995-04-06
WO1985002610A1
(en)
1985-06-20
NZ210501A
(en)
1991-08-27
JP3276933B2
(en)
2002-04-22
JPH08269096A
(en)
1996-10-15
ES8802329A1
(en)
1988-05-01
JPH03259098A
(en)
1991-11-19
JP3017962B2
(en)
2000-03-13
US5618698A
(en)
1997-04-08
AU3612597A
(en)
1997-12-18
AU2042192A
(en)
1992-10-08
EP0148605A3
(en)
1987-06-03
NL930128I1
(en)
1993-11-01
JPH1072366A
(en)
1998-03-17
US5441868A
(en)
1995-08-15
JP3375614B2
(en)
2003-02-10
JPH0693000A
(en)
1994-04-05
JPH0776239B2
(en)
1995-08-16
JPH0435159B2
(en)
1992-06-10
AU657555B2
(en)
1995-03-16
CA1339047C
(en)
1997-05-27
HK20093A
(en)
1993-03-19
IL73785A0
(en)
1985-03-31
AU3746785A
(en)
1985-06-26
JP2708099B2
(en)
1998-02-04
JPH11253188A
(en)
1999-09-21
SG92891G
(en)
1992-02-14
Similar Documents
Publication
Publication Date
Title
AU657555B2
(en)
1995-03-16
Production of erythropoietin
ZA849625B
(en)
1985-08-28
Production of erythropoietin
AU561634B2
(en)
1987-05-14
Production of microcapsules
AU2755784A
(en)
1984-11-08
Production of phenol
AU2755884A
(en)
1984-11-08
Production of phenol
AU561116B2
(en)
1987-04-30
Production of cellulose
AU571112B2
(en)
1988-03-31
Production of mouldings
AU564671B2
(en)
1987-08-20
Production of nitrodiarylamines
AU558388B2
(en)
1987-01-29
Production of n-acylphenylalanines
AU565836B2
(en)
1987-10-01
Production of aluminium
AU3096384A
(en)
1985-05-16
Production of alumina
AU569099B2
(en)
1988-01-21
Production of beta-phenylserine
AU565507B2
(en)
1987-09-17
Production of aminobenzylamines
AU570519B2
(en)
1988-03-17
Production of cross-bonded starch
AU8164582A
(en)
1982-09-23
Production of chloroackanes
AU688723B3
(en)
1998-02-19
Production of erythropoietin
AU6981798A
(en)
1998-08-20
Production of erythropoietin
LTIP1481A
(en)
1995-06-26
Method for the production of erythropoietin
AU553611B2
(en)
1986-07-24
Production of hydroxymethylbutenoic acids
AU569344B2
(en)
1988-01-28
Production of 4-alkoxyanilines
AU552351B2
(en)
1986-05-29
Production of cobalt-chloride
AU567142B2
(en)
1987-11-12
Production of cephalosporin-c
AU570622B2
(en)
1988-03-24
Production of hollow-ware
PT81213A
(en)
1985-10-01
Process for the production of erythropoietin
AU600650C
(en)
1994-03-03
Polypeptides of erythropoietin
None